Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

IL6 elevation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

IL6 elevation	HER2 Positive Breast Cancer	IL6 elevation	HER2 Positive Breast Cancer	trastuzumab Sensitive: C3 – Early Trials Altern Ther Health Med - 3 weeks (New C3) trastuzumab Sensitive : C3 Altern Ther Health Med - 3wk	trastuzumab Sensitive: C3 – Early Trials Altern Ther Health Med - 3 weeks trastuzumab Sensitive : C3 Altern Ther Health Med - 3 weeks - (New C3)
IL6 elevation	Melanoma	IL6 elevation	Melanoma	ipilimumab Resistant: B - Late Trials ipilimumab Resistant : B	ipilimumab Resistant: B - Late Trials ipilimumab Resistant : B
IL6 elevation	Melanoma	IL6 elevation	Melanoma	nivolumab + ipilimumab Resistant: B - Late Trials nivolumab + ipilimumab Resistant : B	nivolumab + ipilimumab Resistant: B - Late Trials nivolumab + ipilimumab Resistant : B
IL6 elevation	Gastric Cancer	IL6 elevation	Gastric Cancer	nivolumab + ramucirumab Sensitive: C3 – Early Trials nivolumab + ramucirumab Sensitive : C3	nivolumab + ramucirumab Sensitive: C3 – Early Trials nivolumab + ramucirumab Sensitive : C3
IL6 elevation	Non Small Cell Lung Cancer	IL6 elevation	Non Small Cell Lung Cancer	ABBV-181 Sensitive: C3 – Early Trials ABBV-181 Sensitive : C3	ABBV-181 Sensitive: C3 – Early Trials ABBV-181 Sensitive : C3
IL6 elevation	Cervical Cancer	IL6 elevation	Cervical Cancer	ipilimumab Resistant: C3 – Early Trials ipilimumab Resistant : C3	ipilimumab Resistant: C3 – Early Trials ipilimumab Resistant : C3
IL6 elevation	Melanoma	IL6 elevation	Melanoma	nivolumab Resistant: C3 – Early Trials nivolumab Resistant : C3	nivolumab Resistant: C3 – Early Trials nivolumab Resistant : C3
IL6 elevation	Small Cell Lung Cancer	IL6 elevation	Small Cell Lung Cancer	ipilimumab Resistant: C3 – Early Trials ipilimumab Resistant : C3	ipilimumab Resistant: C3 – Early Trials ipilimumab Resistant : C3
IL6 elevation	Uveal Melanoma	IL6 elevation	Uveal Melanoma	tebentafusp Sensitive: C3 – Early Trials tebentafusp Sensitive : C3	tebentafusp Sensitive: C3 – Early Trials tebentafusp Sensitive : C3
IL6 elevation	Renal Cell Carcinoma	IL6 elevation	Renal Cell Carcinoma	pazopanib Resistant: C3 – Early Trials pazopanib Resistant : C3	pazopanib Resistant: C3 – Early Trials pazopanib Resistant : C3
IL6 elevation	Renal Cell Carcinoma	IL6 elevation	Renal Cell Carcinoma	sunitinib Resistant: C3 – Early Trials sunitinib Resistant : C3	sunitinib Resistant: C3 – Early Trials sunitinib Resistant : C3
IL6 elevation	Renal Cell Carcinoma	IL6 elevation	Renal Cell Carcinoma	sunitinib + pazopanib Resistant: C3 – Early Trials sunitinib + pazopanib Resistant : C3	sunitinib + pazopanib Resistant: C3 – Early Trials sunitinib + pazopanib Resistant : C3
IL6 elevation	Clear Cell Renal Cell Carcinoma	IL6 elevation	Clear Cell Renal Cell Carcinoma	nivolumab Resistant: C3 – Early Trials nivolumab Resistant : C3	nivolumab Resistant: C3 – Early Trials nivolumab Resistant : C3
IL6 elevation	Hepatocellular Cancer	IL6 elevation	Hepatocellular Cancer	bevacizumab + atezolizumab Resistant: C3 – Early Trials bevacizumab + atezolizumab Resistant : C3	bevacizumab + atezolizumab Resistant: C3 – Early Trials bevacizumab + atezolizumab Resistant : C3
IL6 elevation	Diffuse Large B Cell Lymphoma	IL6 elevation	Diffuse Large B Cell Lymphoma	axicabtagene ciloleucel Resistant: C3 – Early Trials axicabtagene ciloleucel Resistant : C3	axicabtagene ciloleucel Resistant: C3 – Early Trials axicabtagene ciloleucel Resistant : C3
IL6 elevation	Melanoma	IL6 elevation	Melanoma	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
IL6 elevation	Renal Cell Carcinoma	IL6 elevation	Renal Cell Carcinoma	pembrolizumab + axitinib Resistant: C3 – Early Trials pembrolizumab + axitinib Resistant : C3	pembrolizumab + axitinib Resistant: C3 – Early Trials pembrolizumab + axitinib Resistant : C3
IL6 elevation	Mantle Cell Lymphoma	IL6 elevation	Mantle Cell Lymphoma	TG-1701 Sensitive: D – Preclinical TG-1701 Sensitive : D	TG-1701 Sensitive: D – Preclinical TG-1701 Sensitive : D
IL6 elevation	Mantle Cell Lymphoma	IL6 elevation	Mantle Cell Lymphoma	umbralisib + ublituximab + TG-1701 Sensitive: D – Preclinical umbralisib + ublituximab + TG-1701 Sensitive : D	umbralisib + ublituximab + TG-1701 Sensitive: D – Preclinical umbralisib + ublituximab + TG-1701 Sensitive : D